To the full analysis
AtriCure stock: growth
ATRCAtriCure reported $534.53M in revenue for fiscal 2025, up 14.9% on the prior year, up 20.9% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
14.9%
per year from 2006 to 2025, per share 6.9%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 20.9% | 15.2% | 14.9% |
| Revenue per share | 18.0% | 9.2% | 6.9% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $38.24M | −$13.72M | −$14.15M |
| 2007 | $48.31M | −$11.25M | −$11.16M |
| 2008 | $55.26M | −$10.17M | −$7.46M |
| 2009 | $54.53M | −$16.49M | −$940.51K |
| 2010 | $59.01M | −$3.79M | −$1.85M |
| 2011 | $64.4M | −$5.46M | −$3.51M |
| 2012 | $70.25M | −$7.53M | −$4.92M |
| 2013 | $81.89M | −$11.46M | −$8.09M |
| 2014 | $107.45M | −$16.21M | −$30.81M |
| 2015 | $129.76M | −$27.21M | −$31.84M |
| 2016 | $155.11M | −$33.34M | −$22.81M |
| 2017 | $174.72M | −$26.89M | −$15.33M |
| 2018 | $201.63M | −$21.14M | −$10.38M |
| 2019 | $230.81M | −$35.19M | −$27.99M |
| 2020 | $206.53M | −$48.16M | −$25.13M |
| 2021 | $274.33M | $50.2M | −$23.53M |
| 2022 | $330.38M | −$46.47M | −$39.02M |
| 2023 | $399.25M | −$30.44M | −$37.51M |
| 2024 | $465.31M | −$44.7M | −$11.26M |
| 2025 | $534.53M | −$11.45M | $48.28M |
Revenue by region
Where AtriCure, Inc. generates its revenue.
- U [S]81%
- Outside the US19%
Figures as a table
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|
| U [S] | $185.83M | $169.24M | $229.13M | $277.2M | $333.54M | $382.82M | $435.37M | 81.4% |
| Outside the US | $44.98M | $37.29M | $45.2M | $53.18M | $65.7M | $82.49M | $99.16M | 18.6% |
| Total revenue | $230.81M | $206.53M | $274.33M | $330.38M | $399.25M | $465.31M | $534.53M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.